Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.57 (market cap $116.30B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.63. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| BMY | VNQI | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $50.76 |
52-Week Low | $42.60 | $43.26 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.11, down 0.94% with bearish technical signals from moving averages. The ETF provides international real estate diversification with 682 holdings across 30+ countries, featuring a 0.12% expense ratio and 4.6% dividend yield. Recent analysis highlights its cost advantage over competitors but notes underperformance in total returns compared to domestic REIT ETFs over the past five years.
The outlook remains cautious due to technical weakness and mixed performance history. Investment opportunity lies in global diversification and attractive yield, though risks include currency exposure and slower international real estate recovery. Analyst sentiment is neutral with recovery potential noted as global transaction volumes are expected to increase over 10% in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
